For the quarter ended December 2025, Teva Pharmaceutical Industries Ltd. (TEVA Quick QuoteTEVA - Free Report) reported revenue of $4.71 billion, up 11.4% over the same period last year. EPS came in at $0.96, compared to $0.71 in the year-ago quarter.

The reported revenue represents a surprise of +8.58% over the Zacks Consensus Estimate of $4.34 billion. With the consensus EPS estimate being $0.65, the EPS surprise was +48.45%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Teva Pharmaceutical Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Geographic Revenue- United States: $2.64 billion versus the four-analyst average estimate of $2.15 billion. The reported number represents a year-over-year change of +33.8%.
• Geographic Revenue- Europe: $1.31 billion compared to the $1.32 billion average estimate based on four analysts. The reported number represents a change of -2.9% year over year.
• Geographic Revenue- International Markets: $528 million versus $625.03 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -20.1% change.
• Geographic Revenue- United States- AUSTEDO: $725 million versus the three-analyst average estimate of $584.73 million. The reported number represents a year-over-year change of +40%.
• Geographic Revenue- United States- Anda: $366 million versus $390.22 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -9% change.
• Geographic Revenue- Europe- COPAXONE: $45 million versus $26.59 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -10% change.
• Geographic Revenue- Europe- Respiratory products: $65 million versus the three-analyst average estimate of $57.29 million. The reported number represents a year-over-year change of +6.6%.
• Geographic Revenue- International Markets- Generic products: $422 million versus the three-analyst average estimate of $446.04 million. The reported number represents a year-over-year change of -15.1%.
• Geographic Revenue- International Markets- COPAXONE: $6 million versus $5.14 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -33.3% change.
• Geographic Revenue- United States- AJOVY: $105 million versus the three-analyst average estimate of $70.98 million. The reported number represents a year-over-year change of +66.7%.
• Revenue- COPAXONE- Total: $128 million compared to the $63.5 million average estimate based on two analysts. The reported number represents a change of +4.9% year over year.
• Revenue- API sales to third parties: $136 million versus the two-analyst average estimate of $154.37 million. The reported number represents a year-over-year change of -6.2%.

View all Key Company Metrics for Teva Pharmaceutical Industries here>>>

Shares of Teva Pharmaceutical Industries have returned +3.8% over the past month versus the Zacks S&P 500 composite's +0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.